ReviewInternational journal of molecular sciences2021
Aptamers for Anti-Viral Therapeutics and Diagnostics.
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 43 citations in OpenAlex.
- An integrated Aptamer-CRISPR-Cas12a method for rapid and sensitive detection of carbendazim.Scientific reports · 2025Article
- Development of RNA Aptamers That Inhibit the RNA-Dependent RNA Polymerase Activity of SARS-CoV-2 Strains In Vitro.International journal of molecular sciences · 2025Article
- Screening and characterization of nucleic acid aptamers targeting Brucella surface antigens: identification and analysis of their corresponding binding sites.World journal of microbiology & biotechnology · 2025Article
- RNA aptamer-mediated RNA nanotechnology for potential treatment of cardiopulmonary diseases.Pharmacological research · 2025Review
- Current developments of SELEX technologies and prospects in the aptamer selection with clinical applications.Journal, genetic engineering & biotechnology · 2024Review
- Article
- Development of Aptamers for RNase Inactivation in Xtract-Free™ Sample Collection and Transport Medium.Diagnostics (Basel, Switzerland) · 2024Article
- Generation of hepatitis C virus-resistant liver cells by genome editing-mediated stable expression of RNA aptamer.Molecular therapy. Methods & clinical development · 2023Article
- DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design.PLoS computational biology · 2023Article
- Tryptophan-like side chain holding aptamers inhibit respiratory syncytial virus infection of lung epithelial cells.Scientific reports · 2023Article
- Aptamers: A prospective tool for infectious diseases diagnosis.Journal of clinical laboratory analysis · 2022Review
- Blood-based biomarkers for diagnosis, prognosis, and severity prediction of COVID-19: Opportunities and challenges.Journal of family medicine and primary care · 2022Review
- Design and Functional Analysis of Heterobifunctional Multivalent Phage Capsid Inhibitors Blocking the Entry of Influenza Virus.Bioconjugate chemistry · 2022Article
- Therapeutic Application of Genome Editing Technologies in Viral Diseases.International journal of molecular sciences · 2022Review
- Aptamers for Viral Detection and Inhibition.ACS infectious diseases · 2022Review
- Enzyme linked oligonucleotide assay for the sensitive detection of SARS-CoV-2 variants.Frontiers in cellular and infection microbiology · 2022Article
- Aptamers Against COVID-19: An Untested Opportunity.Mini reviews in medicinal chemistry · 2022Article
- Aptamer Applications in Neuroscience.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Aptamer-based diagnostic and therapeutic approaches in animals: Current potential and challenges.Saudi journal of biological sciences · 2021Review
- Aptamer Applications in Emerging Viral Diseases.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Viral infections cause a host of fatal diseases and seriously affect every form of life from bacteria to humans. Although most viral infections can receive appropriate treatment thereby limiting damage to life and livelihood with modern medicine and early diagnosis, new types of viral infections are continuously emerging that need to be properly and timely treated. As time is the most important factor in the progress of many deadly viral diseases, early detection becomes of paramount importance for effective treatment. Aptamers are small oligonucleotide molecules made by the systematic evolution of ligands by exponential enrichment (SELEX). Aptamers are characterized by being able to specifically bind to a target, much like antibodies. However, unlike antibodies, aptamers are easily synthesized, modified, and are able to target a wider range of substances, including proteins and carbohydrates. With these advantages in mind, many studies on aptamer-based viral diagnosis and treatments are currently in progress. The use of aptamers for viral diagnosis requires a system that recognizes the binding of viral molecules to aptamers in samples of blood, serum, plasma, or in virus-infected cells. From a therapeutic perspective, aptamers target viral particles or host cell receptors to prevent the interaction between the virus and host cells or target intracellular viral proteins to interrupt the life cycle of the virus within infected cells. In this paper, we review recent attempts to use aptamers for the diagnosis and treatment of various viral infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.